Diabetes, Vol 36, Issue 7 796-801, Copyright © 1987 by American Diabetes Association
Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocin
KC Herold, AG Montag and FW Fitch
The importance of T-lymphocytes in the induction of insulitis and
hyperglycemia in certain strains of mice treated with multiple
subdiabetogenic doses of streptozocin has been a matter of controversy. To
understand the role of T-lymphocytes, we treated thymectomized BALB/c ByJ
mice with five daily doses of streptozocin (45 mg/kg) and determined the
effect of treatment with monoclonal antibodies against T-lymphocyte subsets
on the development of diabetes and insulitis. Hyperglycemia (mean glucose
of 321 +/- 29 vs. 167 +/- 15 mg/dl in controls) and insulitis were induced
in BALB/c ByJ mice given streptozocin. Thy1.2+, L3T4, and Lyt2+ cells were
all identified within the islets of diabetic mice. There was a relative
paucity of L3T4+ cells and an overabundance of Lyt2+ cells compared with
the frequency of these cells found in lymphatic tissues or peripheral
blood. Treatment with anti-L3T4 or anti-Lyt2 monoclonal antibodies caused a
reduction in splenic T-lymphocyte subsets and attenuated the hyperglycemia
to 212 +/- 14 and 197 +/- 16 mg/dl (P less than .001 and .01),
respectively, compared with controls and prevented the insulitis induced by
streptozocin. Our studies support the hypothesis that an immune response is
important to the development of multi-low-dose streptozocin diabetes and
indicate that treatment with monoclonal antibodies against the L3T4+ or
Lyt2+ T-lymphocyte subsets can attenuate this process.